Invention Grant
- Patent Title: Combinations of an FGFR inhibitor and an IGF1R inhibitor
-
Application No.: US15128347Application Date: 2015-03-26
-
Publication No.: US10736900B2Publication Date: 2020-08-11
- Inventor: Eleonora Jovcheva , Timothy Pietro Suren Perera
- Applicant: ASTEX THERAPEUTICS LTD
- Applicant Address: GB Cambridge
- Assignee: ASTEX THERAPEUTICS LTD
- Current Assignee: ASTEX THERAPEUTICS LTD
- Current Assignee Address: GB Cambridge
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@1111ea22
- International Application: PCT/EP2015/056518 WO 20150326
- International Announcement: WO2015/144808 WO 20151001
- Main IPC: A61K31/53
- IPC: A61K31/53 ; A61K31/498 ; A61K31/4985 ; A61K31/519
Abstract:
The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.
Public/Granted literature
- US20170100406A1 COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR Public/Granted day:2017-04-13
Information query
